SARS COV-2 infection causes acute and frequently severe respiratory disease with associated multi-organ damage and systemic disturbances in many biochemical pathways.Metabolic phenotyping provides deep insights into t...SARS COV-2 infection causes acute and frequently severe respiratory disease with associated multi-organ damage and systemic disturbances in many biochemical pathways.Metabolic phenotyping provides deep insights into the complex immunopathological problems that drive the resulting COVID-19 disease and is also a source of novel metrics for assess-ing patient recovery.A multiplatform metabolic phenotyping approach to studying the pathology and systemic metabolic sequelae of COVID-19 is considered here,together with a framework for assessing post-acute COVID-19 Syndrome(PACS)that is a major long-term health consequence for many patients.The sudden emergence of the disease presents a biological discovery challenge as we try to understand the pathological mechanisms of the disease and develop effective mitigation strategies.This requires technologies to measure objectively the extent and sub-phenotypes of the disease at the molecular level.Spectroscopic methods can reveal metabolic sub-phenotypes and new biomarkers that can be monitored during the acute disease phase and beyond.This approach is scalable and translatable to other pathologies and provides as an exem-plar strategy for the investigation of other emergent zoonotic diseases with complex immunological drivers,multi-system involvements and diverse persistent symptoms.展开更多
文摘SARS COV-2 infection causes acute and frequently severe respiratory disease with associated multi-organ damage and systemic disturbances in many biochemical pathways.Metabolic phenotyping provides deep insights into the complex immunopathological problems that drive the resulting COVID-19 disease and is also a source of novel metrics for assess-ing patient recovery.A multiplatform metabolic phenotyping approach to studying the pathology and systemic metabolic sequelae of COVID-19 is considered here,together with a framework for assessing post-acute COVID-19 Syndrome(PACS)that is a major long-term health consequence for many patients.The sudden emergence of the disease presents a biological discovery challenge as we try to understand the pathological mechanisms of the disease and develop effective mitigation strategies.This requires technologies to measure objectively the extent and sub-phenotypes of the disease at the molecular level.Spectroscopic methods can reveal metabolic sub-phenotypes and new biomarkers that can be monitored during the acute disease phase and beyond.This approach is scalable and translatable to other pathologies and provides as an exem-plar strategy for the investigation of other emergent zoonotic diseases with complex immunological drivers,multi-system involvements and diverse persistent symptoms.
